Cell-based immunotherapy in solid organ transplantation to minimize systemic immunosuppression

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514866-37-01

Acronym

1311

Enrollment

Registered

2024-10-17

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with end-stage liver disease undergoing liver transplantation with deceased donor organ

Brief summary

Safety evaluation of the protocol at 12 months after deceased donor liver transplantation.

Detailed description

Percentage of patients that are completely weaned of immunosuppression at 36 months after liver transplantation with preserved optimal liver function, and level of immunosuppression used in patients not completely weaned from immunosuppression at the same time point

Interventions

DRUGDonor specific immunomodulatory cells (DSIMC)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Safety evaluation of the protocol at 12 months after deceased donor liver transplantation.	—

Secondary

Measure	Time frame
Percentage of patients that are completely weaned of immunosuppression at 36 months after liver transplantation with preserved optimal liver function, and level of immunosuppression used in patients not completely weaned from immunosuppression at the same time point	—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026